COMP <GO>
TGTX vs CORT // EV/EBITDA & P/E VALUATION
TG Therapeutics Inc. (NASDAQ) VS. Corcept Therapeutics Incorporated (NASDAQ) • 15-METRIC TALLY: TGTX 8
— CORT 5
▲ EV/EBITDA & P/E VALUATION LEADER: TGTX
LAST: $59.95 (-2.01%) • MKT CAP: $9.36B
valuation
73.3x
LAST: $80.46 (-0.81%) • MKT CAP: $8.77B
valuation
95.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TGTX VS. CORT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TGTX | CORT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 83.70% | 96.00% | -12.30 | CORT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.00% | 4.80% | +7.20 | TGTX | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 73.3x | 95.0x | -21.70 | TGTX | /valuation <GO> |
| Free Cash Flow Yield | -0.28% | 1.53% | -1.81 | CORT | /fcf-yield <GO> |
| Operating Margin | 20.00% | 5.90% | +14.10 | TGTX | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 13.10% | +54.90 | TGTX | /net-margins <GO> |
| Revenue Growth (YoY) | 87.30% | 12.80% | +74.50 | TGTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.92 | 26.00 | -13.08 | CORT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | CORT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.7 | 27.6 | +37.10 | TGTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 0.88 | -0.01 | CORT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 16.7x | 78.3x | -61.60 | TGTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.36B | $8.77B | $595.8M | TGTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TGTX REV | CORT REV | TGTX GROSS % | CORT GROSS % | TGTX FCF | CORT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $616.3M | $761.4M | 83.7% | 98.3% | -$25.0M | $141.8M |
| FY 2024 | $329.0M | $675.0M | 88.3% | 98.4% | -$40.6M | $196.1M |
| FY 2023 | $233.7M | $482.4M | — | — | -$41.9M | $105.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TGTX // BETA 0.87
CORT // BETA 0.88